Carl P. Sherr & Co., LLC Abb Vie Inc. Transaction History

Carl P. Sherr & Co., LLC

$188 Million
Q3 2024

A detailed history of Carl P. Sherr & Co., LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Carl P. Sherr & Co., LLC holds 4,853 shares of ABBV stock, worth $800,696. This represents 0.51% of its overall portfolio holdings.

Number of Shares

4,853

Previous 4,853 -0.0%

Holding current value

$800,696

Previous $832,000 15.14%

% of portfolio

0.51%

Previous 0.46%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 23, 2024	SELL	$154.79 - $180.76 $64,547 - $75,376	-417 Reduced 7.91%	4,853 $832,000
Q4 2023 Jan 30, 2024	SELL	$137.6 - $154.97 $27,520 - $30,994	-200 Reduced 3.66%	5,270 $816,000
Q4 2022 Feb 02, 2023	SELL	$138.31 - $165.87 $553 - $663	-4 Reduced 0.07%	5,470 $884,000
Q3 2022 Nov 10, 2022	BUY	$134.21 - $153.93 $96,765 - $110,983	721 Added 15.17%	5,474 $735,000
Q2 2022 Aug 03, 2022	BUY	$137.62 - $174.96 $48,167 - $61,236	350 Added 7.95%	4,753 $728,000
Q1 2022 May 03, 2022	SELL	$131.98 - $163.75 $46,193 - $57,312	-350 Reduced 7.36%	4,403 $714,000
Q4 2021 Feb 11, 2022	BUY	$107.43 - $135.93 $30,617 - $38,740	285 Added 6.38%	4,753 $644,000
Q1 2021 Apr 13, 2021	SELL	$102.3 - $112.62 $2,148 - $2,365	-21 Reduced 0.47%	4,468 $484,000
Q4 2020 Feb 08, 2021	BUY	$80.49 - $108.67 $1,690 - $2,282	21 Added 0.47%	4,489 $481,000
Q1 2020 Jul 28, 2020	BUY	$64.5 - $97.79 $4,837 - $7,334	75 Added 1.71%	4,468 $340,000
Q4 2019 Jul 28, 2020	BUY	$72.13 - $90.25 $316,867 - $396,468	4,393 New	4,393 $389,000

Others Institutions Holding ABBV

# of Institutions

3,841

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $292B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Carl P. Sherr & Co., LLC, based on Form 13F filings with the SEC.

News

Stay updated on Carl P. Sherr & Co., LLC with notifications on news.

Account

Carl P. Sherr & Co., LLC Abb Vie Inc. Transaction History